I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Iluvien for Diabetic Macular Edema: What Patients Need to Know
What Is Diabetic Macular Edema?
Diabetic macular edema is one of the most common causes of vision loss among people with diabetes. Understanding how it develops helps explain why a sustained treatment approach like Iluvien can be beneficial in certain cases.
Over time, elevated blood sugar levels from diabetes damage the small blood vessels throughout the body, including those inside the eye. In the retina (the light-sensitive tissue lining the back of the eye), these damaged vessels become fragile and begin leaking fluid and proteins into the surrounding tissue.
The macula is the small central area of the retina responsible for sharp, detailed vision. We use it for reading, recognizing faces, and performing tasks that require fine detail. When fluid from leaky blood vessels accumulates in and around the macula, it swells, which disrupts the macula's ability to process images clearly.
Symptoms of DME can include blurred vision, difficulty reading, straight lines appearing wavy, and colors looking faded or washed out. These changes may develop gradually and can affect one or both eyes. Because macular edema can be present without noticeable symptoms in its early stages, regular dilated eye examinations are important for all patients with diabetes.
Inflammation plays a key role in the development and persistence of DME. When blood vessels leak, inflammatory signals attract immune cells to the affected area, which can worsen vessel damage and drive further fluid accumulation. This ongoing inflammatory cycle is one reason why corticosteroid medications, which suppress inflammation broadly, can be effective for DME, particularly when swelling has not resolved with other treatments.
How Iluvien Works
Iluvien targets the inflammatory pathways that drive macular swelling through a sustained-release implant design. Its small size and extended duration distinguish it from other treatment approaches for diabetic macular edema.
The active ingredient in Iluvien is fluocinolone acetonide, a synthetic corticosteroid. Inside the eye, it works by blocking multiple inflammatory proteins called cytokines, which reduces swelling and limits additional fluid leakage from damaged blood vessels. It also reduces the effects of vascular endothelial growth factor (VEGF), a protein that promotes blood vessel permeability and contributes to macular edema.
The Iluvien implant is approximately 3.5 millimeters long, roughly the size of a grain of rice, and is placed into the vitreous, the clear gel that fills the inside of the eye. From there, it releases fluocinolone acetonide at a continuous, low dose for approximately 36 months.
The implant is non-biodegradable, meaning it does not dissolve after the medication is fully released. It remains in the eye permanently but does not need to be surgically removed.
Most other treatments for DME require injections every four to eight weeks or more. Iluvien's steady release of medication maintains consistent drug levels inside the eye for approximately three years from a single implant. This provides an uninterrupted anti-inflammatory effect and reduces the total number of procedures required during the treatment period.
What the Evidence Shows
Iluvien's FDA approval was supported by clinical trial data demonstrating meaningful improvements in vision and macular thickness in patients with diabetic macular edema. The key evidence comes from the FAME clinical program.
The FAME (Fluocinolone Acetonide in Diabetic Macular Edema) program included two large Phase 3 trials enrolling nearly 1,000 patients with DME. Participants were assigned to receive either the fluocinolone acetonide implant or a sham (inactive) procedure and were followed for up to 36 months.
At 24 months, a significantly higher percentage of patients treated with Iluvien achieved a clinically meaningful improvement in vision compared to those in the sham group. The implant also produced a significant reduction in central retinal thickness, confirming real improvement in macular swelling.
The FAME trials identified a subgroup of patients with chronic diabetic macular edema lasting three or more years. These patients showed notably higher rates of meaningful vision gain compared to those with shorter-duration edema. This pattern suggests that patients with long-standing, treatment-resistant DME may benefit the most from Iluvien's sustained anti-inflammatory approach.
Clinical trial results reflect outcomes across a broad population and provide useful guidance, but they do not predict individual results. Each patient's response to treatment depends on factors including baseline vision, duration of DME, overall eye health, and history with prior therapies. Your retina specialist will review your specific situation and help you understand what outcomes are realistic for your case.
Who May Benefit from Iluvien
Iluvien is not the first-line treatment for every patient with DME. It is most appropriate for a specific group of patients whose history and eye health make it a well-matched option.
Iluvien is generally considered for patients whose diabetic macular edema has persisted for a significant period or has not responded adequately to other treatments, including anti-VEGF injections. When anti-VEGF therapy alone does not fully resolve macular swelling, the inflammatory component of DME may be playing a particularly significant role, and a sustained corticosteroid approach can be more effective.
Before recommending Iluvien, your retina specialist will typically evaluate how your eye responds to a shorter-acting corticosteroid first. Because Iluvien delivers medication for approximately three years, it is important to confirm that your eye tolerates corticosteroids without a significant rise in intraocular pressure before committing to such an extended course of treatment. This step helps identify patients who are both likely to respond well and unlikely to develop serious pressure-related complications.
The most common side effect of Iluvien in patients with a natural lens is cataract development, a clouding of the eye's lens that can blur vision. Patients who have already had cataract surgery have an artificial lens in place, which means cataract formation is no longer a concern. For this reason, patients who are already pseudophakic (those with an artificial lens) are often considered particularly well-suited candidates for Iluvien.
The Implant Procedure
The Iluvien implant is placed during a brief in-office procedure. Most patients find it well-tolerated, and the entire appointment typically takes under an hour from preparation to discharge.
Your retina specialist will begin by applying anesthetic drops to numb the surface of your eye. The eye surface is then cleaned with an antiseptic solution to minimize infection risk. Some patients receive additional numbing medication around the eye. You will remain awake throughout the procedure, and your specialist will walk you through each step before it happens.
The implant is preloaded into a specialized inserter with a very fine needle. The needle is gently passed through the white part of the eye (the sclera), and the tiny implant is released into the vitreous space. The actual placement takes only a few seconds.
Most patients feel mild pressure rather than sharp pain during the procedure. Immediately afterward, your eye pressure will be checked before you leave the office.
It is common to notice mild grittiness, slight blurring, or temporary floaters after the implant is placed. These effects typically resolve within a few hours to a day. You can return to most daily activities the same day, though you should avoid rubbing your eye and stay out of dusty or dirty environments for a few days to help reduce infection risk.
Because your vision may be temporarily affected by the anesthetic drops and the procedure itself, please arrange for someone to drive you home from your appointment.
Benefits and Risks
Like all medical treatments, Iluvien carries both potential benefits and known risks. Your retina specialist will help you weigh these carefully based on your individual health history and the severity of your condition.
Iluvien provides continuous anti-inflammatory treatment for approximately three years from a single implant. For patients with chronic DME, this can reduce macular swelling, help stabilize or improve vision, and significantly reduce the number of in-office procedures needed compared to injection-based therapies that require visits every four to eight weeks.
Cataract development is the most common side effect of Iluvien in patients who have not already had cataract surgery. In clinical trials, cataracts developed in approximately 82 percent of treated patients with a natural lens over 36 months, compared to 50 percent in the sham group. Most patients who developed cataracts required cataract surgery.
If you develop a visually significant cataract during treatment, your eye care team can evaluate and plan cataract removal when appropriate. Patients who have already had cataract surgery do not face this risk.
Corticosteroids can raise intraocular pressure (IOP), the fluid pressure inside the eye. Elevated IOP, if not managed, can harm the optic nerve, so close monitoring throughout treatment is essential. In clinical trials, a meaningful portion of patients experienced IOP elevations above safe thresholds during the 36-month treatment period, with a smaller number requiring a surgical procedure to control pressure.
Most cases of elevated IOP can be managed effectively with pressure-lowering eye drops. Your retina specialist will monitor your IOP closely, particularly during the first several months after implantation when changes are most likely to occur.
Less common but serious risks include eye infection (endophthalmitis), retinal detachment, bleeding inside the eye (vitreous hemorrhage), and movement of the implant within the eye. Contact our office or go to an emergency room immediately if you experience any of the following after the procedure.
- Sudden vision loss
- Severe or worsening eye pain
- A dramatic increase in floaters
- New flashes of light in your vision
- Sudden distortion in your central vision
These complications are uncommon but can indicate a serious problem that requires prompt evaluation and care.
Treatment Schedule and Monitoring
Because Iluvien provides sustained treatment for approximately three years, your schedule of procedures looks very different from anti-VEGF therapy. However, regular follow-up visits remain essential throughout the entire treatment period.
A single Iluvien implant releases fluocinolone acetonide continuously for approximately 36 months. After this period, the medication supply is depleted, but the implant itself remains in the eye. Your retina specialist will assess your macular health as the treatment period nears its end and discuss options for continued care.
Even though Iluvien reduces the frequency of injections, in-person monitoring visits remain critical to safe and effective treatment. At each appointment, your retina specialist will measure your visual acuity, assess macular thickness using optical coherence tomography (OCT, a non-invasive imaging scan of the retina), and check your intraocular pressure.
Monitoring visits may be scheduled monthly for the first several months after implantation and then at longer intervals based on your individual response. If your IOP rises or other concerns emerge, your care team can respond promptly to protect your eye health.
If macular edema returns or worsens after the medication supply is exhausted, your retina specialist may recommend a second Iluvien implant or an alternative treatment approach. Because the implant does not dissolve, prior implants remain in the eye alongside any new ones placed later. Your specialist will take your full treatment history and current eye health into account when making any retreatment recommendation.
How Iluvien Compares to Other Treatments
Iluvien is one of several options for managing diabetic macular edema. Understanding where it fits within the treatment landscape supports a more informed conversation with your retina specialist about what approach is right for you.
Ozurdex (dexamethasone intravitreal implant) is another corticosteroid option used for DME. Unlike Iluvien, Ozurdex is biodegradable and dissolves over time, releasing medication for approximately four to six months. Iluvien releases medication for approximately 36 months, making it a much longer-lasting option.
A shorter-acting implant like Ozurdex may be used to evaluate how your eye responds to corticosteroid therapy before committing to a longer course, or for patients who prefer a shorter treatment cycle. Iluvien is generally preferred for patients with chronic DME who need sustained, long-term treatment.
Anti-VEGF injections are currently the most widely used first-line treatment for diabetic macular edema. These medications block VEGF, a protein that drives blood vessel leakage, and they require repeated in-office injections, typically every four to eight weeks. They do not carry the risks of elevated eye pressure or cataract development associated with corticosteroids.
Iluvien is most often considered when anti-VEGF therapy alone has not adequately controlled macular swelling, or when the inflammatory component of a patient's DME is particularly prominent. In some cases, your retina specialist may recommend using both approaches in combination, depending on your individual needs and response to treatment.
Frequently Asked Questions
Here are answers to questions our patients commonly ask when learning about Iluvien as a treatment option for diabetic macular edema.
No. The implant is small enough to remain in the eye permanently without causing problems, and it does not require surgical removal after the medication is depleted. If you receive additional implants over the course of your care, they can coexist in the eye. Your retina specialist will confirm at each monitoring visit that all implants are properly positioned and not interfering with your vision or overall eye health.
Most patients do not feel the implant once it has settled into position. You may notice a temporary gritty sensation or the feeling that something is in your eye during the first day or two after the procedure, but this typically resolves quickly. Because the implant is positioned in the vitreous, away from the front surface of the eye, it does not cause ongoing discomfort for the vast majority of patients.
Not every patient will experience a significant improvement in vision with Iluvien. In some cases, the primary goal of treatment is to stabilize vision and prevent further decline rather than to restore what has already been lost. If your macular edema does not respond adequately, your retina specialist may adjust your treatment plan, which could involve adding or switching to a different therapy. Attending every scheduled monitoring visit is the best way to track your progress and make timely decisions about your care.
Iluvien can be placed in both eyes if both are affected by diabetic macular edema. However, bilateral treatment decisions are made carefully, taking into account each eye's individual response to corticosteroids, current intraocular pressure, prior surgical history, and overall eye health. Your retina specialist will evaluate each eye separately before recommending treatment for both, and the timing may be staggered to allow for safer monitoring of your response.
Before receiving Iluvien, let your retina specialist know about any personal or family history of elevated eye pressure or glaucoma (a condition involving optic nerve damage from high eye pressure), any prior eye surgeries, any known medication allergies, and whether you currently take blood-thinning medications or supplements. Sharing this information allows your physician to anticipate potential complications and personalize your care plan before treatment begins.
Yes. In 2025, the FDA approved Iluvien for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Uveitis refers to inflammation inside the eye that is not caused by an infection. The same implant is used for both indications, but the decision about how to treat the underlying condition and what monitoring is needed requires individualized guidance from your retina specialist based on your full clinical picture.
Schedule a Consultation at New England Retina Associates
At New England Retina Associates, our fellowship-trained retina specialists have extensive experience evaluating and treating diabetic macular edema and guiding patients through every available treatment option, including Iluvien, across all four of our Connecticut offices. Whether you have been referred by another eye care provider or are seeking care on your own, we welcome you and are committed to helping you understand your diagnosis and make confident, informed decisions about your retinal health. We encourage you to reach out and schedule a comprehensive retina evaluation with our team.
30 Years of Care & Commitment
